survival rates

Pharma

Pfizer, Astellas' Xtandi scores Bayer-matching survival win

Pfizer and Astellas' Xtandi is chasing Bayer's challenger in extending patient lives in a hard-to-treat form of prostate cancer. New data should help.

Kyle Blankenship Feb 11, 2020 9:54am

AstraZeneca spearheads lung cancer alliance

Jul 22, 2019 8:00am